PD-1 knockout engineered T cells - Chengdu MedGenCell

Drug Profile

PD-1 knockout engineered T cells - Chengdu MedGenCell

Latest Information Update: 14 Jan 2017

Price : $50

At a glance

  • Originator Chengdu MedGenCell
  • Developer Anhui Provincial Hospital; Chengdu MedGenCell; West China Hospital Sichuan University
  • Class Antineoplastics; Cell therapies; Gene therapies; T lymphocyte cell therapies
  • Mechanism of Action PDCD 1 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Lung cancer; Malignant melanoma
  • Phase I Non-small cell lung cancer

Most Recent Events

  • 11 Jan 2017 Phase-II clinical trials in Lung cancer (Late-stage disease, Second-line therapy or greater) in China (Parenteral) (ChiCTR-OIC17010390)
  • 11 Jan 2017 Phase-II clinical trials in Malignant melanoma (Late-stage disease, Second-line therapy or greater) in China (Parenteral) (ChiCTR-OIC17010391)
  • 11 Jan 2017 Anhui Provincial Hospital plans a phase II trial for Lung adenocarcinoma (Late-stage disease, Second-line therapy or greater) in China (Parenteral) (ChiCTR-OIC17010389)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top